Hu3F8 bispecific antibody - Y-mAbs Therapeutics

Drug Profile

Hu3F8 bispecific antibody - Y-mAbs Therapeutics

Alternative Names: Hu3F8-BsAb (GD2xCD3); huGD2-BsAb

Latest Information Update: 17 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Y-mAbs Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; GD2 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ewing's sarcoma; Neuroblastoma; Solid tumours

Most Recent Events

  • 16 Sep 2016 Preclinical trials in Ewing's Sarcoma (In children) in USA (IV) (Y-mAbs Therapeutics pipeline September,
  • 16 Sep 2016 Preclinical trials in Neuroblastoma (In children) in USA (IV) (Y-mAbs Therapeutics pipeline September,
  • 22 Aug 2016 Y-mAbs Therapeutics enters into an agreement for manufacturing of Hu3F8 bispecific antibody
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top